Literature DB >> 31641883

Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).

Irina S Barequet1, Tzukit Zehavi-Dorin2, Nirit Bourla2, Ilia Tamarin3, Joseph Moisseiev2, Ophira Salomon3.   

Abstract

PURPOSE: To evaluate the safety of phacoemulsification of cataract in patients taking new oral anticoagulants (NOACs).
METHODS: In a prospective case series, consecutive patients on NOACs (dabigatran, rivaroxaban, or apixaban) who were referred for uncomplicated cataract surgery to the eye institute underwent a thorough ophthalmological and hematological evaluation. Rivaroxaban and apixaban anti-factor Xa tests, and diluted thrombin time for dabigatran, were used for monitoring anticoagulation levels in blood. Blood was drawn for these tests just prior to surgery and at a peak level of the drug at about 4 h post-surgery (2 h after the drug was given). All surgeries were videotaped and patients were examined at 1 and 7 days after the operation. The main outcome measures included assessment of intra-operative, postoperative ocular bleeding, and other related complications.
RESULTS: Thirty-five eyes of 25 unrelated patients ranging in age from 63 to 92 years (mean 77.6 years) underwent phacoemulsification. Intra-operative bleeding was observed in 5 eyes from the conjunctiva or limbus at the main incision site. No intraocular bleeding occurred. No hemorrhagic complications were observed during the 1-week follow-up. According to anti-factor Xa levels prior to surgery and following surgery, 85% of the patients were on therapeutic levels of NOACs.
CONCLUSIONS: Clear corneal incision phacoemulsification performed under topical anesthesia can be safely performed in simple cases of cataract without discontinuing NOAC treatment.

Entities:  

Keywords:  Anticoagulants; CHA2DS2VASC score; Intraoperative bleeding; NOAC; Phacoemulsification

Year:  2019        PMID: 31641883     DOI: 10.1007/s00417-019-04488-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

Review 1.  Continuation of anticoagulant and antiplatelet therapy during phacoemulsification cataract surgery.

Authors:  Andrzej Grzybowski; Francisco J Ascaso; Konrad Kupidura-Majewski; Mark Packer
Journal:  Curr Opin Ophthalmol       Date:  2015-01       Impact factor: 3.761

Review 2.  Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants: Systematic Review and Meta-analysis.

Authors:  Daniel Caldeira; Mário Canastro; Márcio Barra; Adriana Ferreira; João Costa; Fausto J Pinto; Joaquim J Ferreira
Journal:  JAMA Ophthalmol       Date:  2015-07       Impact factor: 7.389

3.  Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.

Authors:  David Garcia; John H Alexander; Lars Wallentin; Daniel M Wojdyla; Laine Thomas; Michael Hanna; Sana M Al-Khatib; Paul Dorian; Jack Ansell; Patrick Commerford; Greg Flaker; Fernando Lanas; Dragos Vinereanu; Denis Xavier; Elaine M Hylek; Claes Held; Freek W A Verheugt; Christopher B Granger; Renato D Lopes
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

4.  Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients.

Authors:  Cyril Meillon; Pierre Henry Gabrielle; Maxime Luu; Ludwig S Aho-Glele; Alain M Bron; Catherine Creuzot-Garcher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-23       Impact factor: 3.117

5.  Risk of intraocular hemorrhage with new oral anticoagulants.

Authors:  G Talany; M Guo; M Etminan
Journal:  Eye (Lond)       Date:  2016-12-23       Impact factor: 3.775

6.  Perioperative management of new oral anticoagulants in patients undergoing elective surgery at a tertiary hospital.

Authors:  Henry Wamala; Ian A Scott; Xenia Caney
Journal:  Intern Med J       Date:  2017-12       Impact factor: 2.048

Review 7.  Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective.

Authors:  Maureane Hoffman; Dougald M Monroe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-10       Impact factor: 8.311

8.  Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.

Authors:  Joanne Katz; Marc A Feldman; Eric B Bass; Lisa H Lubomski; James M Tielsch; Brent G Petty; Lee A Fleisher; Oliver D Schein
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

9.  Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy.

Authors:  Kevin Wang; Justis P Ehlers
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-01       Impact factor: 1.300

Review 10.  Safety of new oral anticoagulant drugs: a perspective.

Authors:  Juan Antonio Vílchez; Pilar Gallego; Gregory Y H Lip
Journal:  Ther Adv Drug Saf       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.